Assembly Biosciences (NASDAQ:ASMB - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating analysts' consensus estimates of ($2.01) by $0.84, Zacks reports. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%. The firm had revenue of $9.42 million during the quarter, compared to the consensus estimate of $7.41 million.
Assembly Biosciences Stock Up 0.6%
NASDAQ ASMB traded up $0.07 during trading hours on Tuesday, hitting $12.42. The company had a trading volume of 8,045 shares, compared to its average volume of 25,785. The firm has a market cap of $94.86 million, a P/E ratio of -1.99 and a beta of 0.49. Assembly Biosciences has a fifty-two week low of $7.75 and a fifty-two week high of $19.93. The business has a fifty day simple moving average of $10.59 and a 200-day simple moving average of $13.49.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on the stock. StockNews.com lowered shares of Assembly Biosciences from a "buy" rating to a "hold" rating in a research note on Monday, March 24th. HC Wainwright reiterated a "neutral" rating on shares of Assembly Biosciences in a research note on Monday, March 24th. Finally, Guggenheim started coverage on Assembly Biosciences in a report on Tuesday, March 25th. They set a "buy" rating and a $31.00 target price on the stock.
Read Our Latest Report on ASMB
Assembly Biosciences Company Profile
(
Get Free Report)
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Read More
Before you consider Assembly Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.
While Assembly Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
